Another study identified SOX9 as an independent risk factor for both RFS and overall survival (OS) in HCC patients treated with sorafenib, as it enhances sorafenib resistance through the modulation of ABCG2 [11]. This evidence concerns the gene ABCG2 and hepatocellular carcinoma.